

## HP4 Hepatology Review

**Price:** \$580.00

**Register:** (866) 611-5599 or [www.AmericanSeminar.com](http://www.AmericanSeminar.com)

*\*Special Association accreditation may vary. See website.*

### **Update on Liver Disease - Norman L. Sussman, MD**

Select appropriate treatments for portal hypertension based on severity, cardiac output, and comorbidities; Compare and contrast methods for the management of variceal bleeding in patients with cirrhosis; Assess possible causes and options for the management of sarcopenia in patients with cirrhosis; Identify patients with acute-on-chronic liver failure using clinician assessment or scoring systems; Apply scoring systems to determine eligibility for liver transplantation and probability of survival in patients with acute-on-chronic liver failure.

GE 32 - 07

### **Hepatitis Update - John A. Donovan, MD and Bolin Niu, MD**

Classify the stage of disease in a patient with chronic hepatitis B; Manage hepatitis B in a pregnant woman; Choose among common regimens employing directacting antiviral agents for treatment of hepatitis C; List risk factors for autoimmune hepatitis; Identify patients with autoimmune hepatitis who need pharmacologic treatment or liver transplantation.

IM 65 - 27

### **Liver Chemistries/Liver Preservation - Elliot Tapper, MD and Christopher J. Sonnenday, MD**

Perform an appropriate workup for a patient with elevated alkaline phosphatase.; Counsel patients on lifestyle modification to manage nonalcoholic fatty liver disease; Identify the possible causes of elevated liver enzymes; Describe how machine perfusion improves preservation of donor livers; Explain the concept of warm perfusion for preservation of donor livers.

GE 32 - 15

### **Cirrhosis/Liver Injury - Elliot Tapper, MD and Norman L. Sussman, MD**

Characterize hospital readmission in patients with cirrhosis; Assess the effectiveness of interventions for reducing hospital readmissions of patients with cirrhosis; Identify drugs that commonly cause injury to the liver; Differentiate between immune-mediated and metabolic causes of drug-induced liver injury; List clinical and histologic characteristics of various types of drug-induced liver injury.

GE 32 - 11

### **Liver Transplantation 2018 - David Goldberg, MD and Jonathan M. Fenkel, MD**

Review the principles of allocation used in organ, and particularly liver, transplantation; Explain the concept of liver transplant redistribution (or broader sharing) to improve fairness in geographic access to transplantation; Discuss the concerns involved with HCV-positive donors and HCV-positive recipients in liver transplantation; Describe the advantages and disadvantages of telehealth in transplant hepatology; Identify conditions and situations that lend themselves well to management via telehealth in hepatology

GE 32 - 13

### **Updates on Liver Disease - John A. Donovan, MD, She-Yan Wong, MD and Manish Thapar, MD**

Use common liver function tests to diagnose disorders of the liver; Evaluate a patient with suspected ischemic liver injury; List the expected changes in liver function during pregnancy and assess more concerning symptoms; Manage a patient with intrahepatic cholestasis of pregnancy; Diagnose common porphyrias.

IM 65 - 40

---

## HP4 Hepatology Review

**Price:** \$580.00

**Register:** (866) 611-5599 or [www.AmericanSeminar.com](http://www.AmericanSeminar.com)

*\*Special Association accreditation may vary. See website.*

**Liver Diseases in 2018 - Meena B. Bansal, MD,  
Gina Choi, MD and Gene Im, MD**

Recognize signs and symptoms of sarcoidosis; Treat skin manifestations of sarcoidosis; Counsel patients about BP targets and management, based on updated hypertension guidelines; Implement colorectal cancer screening, based on American College of Gastroenterology guidelines; Compare the recombinant adjuvanted zoster vaccine with the live zoster vaccine.

GE 32 - 20

**Primary Biliary Cholangitis/Fatty Liver - David A.  
Sass, MD and Monica Konerman, MD**

Recognize manifestations of primary biliary cholangitis; Identify risk factors for primary biliary cholangitis; Explain the pathophysiology of nonalcoholic fatty liver disease; Choose appropriate diagnostic tests for the diagnosis of nonalcoholic fatty liver disease; Recommend lifestyle interventions for the management of nonalcoholic fatty liver disease.

GE 33 - 11

**NASH/Cirrhosis and HCV - Amreen Dinani, MD  
and John P. Norvell, MD**

Counsel patients about the importance of lifestyle intervention in the treatment of nonalcoholic steatohepatitis; Identify the potential therapeutic targets for hepatic fibrosis; Characterize drugs currently in development for the treatment of nonalcoholic steatohepatitis; Adopt general principles for the management of hepatitis C-related cirrhosis; Select appropriate candidates for referral to a liver transplantation center.

GE 33 - 12

**Abnormal Liver Function Tests /Diabetic Foot  
Ulcers - Steven-Huy B. Han, MD and Barry M.  
Stults, MD**

Interpret liver function tests and liver enzyme levels; Identify patients with hepatitis, cholestasis, or cholestatic hepatitis based on physical and laboratory findings; Determine whether further workup is indicated in patients with abnormal liver function results; Stratify risk for foot ulcer in diabetic patients; Educate diabetic patients about proper foot care

FP 67 - 26